Cetuximab in non-small cell lung cancer

Foluso O. Ademuyiwa, Nasser Hanna

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalExpert opinion on biological therapy
Issue number1
StatePublished - Jan 1 2008


  • Cetuximab
  • Chemotherapy
  • EGFR antibody
  • Epidermal growth factor receptor inhibitor
  • Non-small cell lung cancer


Dive into the research topics of 'Cetuximab in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this